AKT1 and neoplasm: Silibinin, when given orally to A2780 cells, shrinks the tumor volume, decreases Ki-67-positive cells, increases transferase-mediated dUTP nick end labelling -positive cells, caspase-3 activation, p-ERK, and p-Akt inhibition.